Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: Test-retest variability in lung cancer

Journal of Nuclear Medicine

Volumn 51, Issue 11, 2010, Pages 1684-1690

  Van Der Veldt, Astrid A M ^a   Hendrikse, N Harry ^a   Harms, Hendrik J ^a   Comans, Emile F I ^a   Postmus, Pieter E ^a   Smit, Egbert F ^a   Lammertsma, Adriaan A ^a   Lubberink, Mark ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Lung cancer; Parametric perfusion images; PET CT; Radioactive water; Tumor perfusion

Indexed keywords

WATER O 15;

ADULT; ARTERIAL BLOOD; ARTICLE; ASCENDING AORTA; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMAGE QUALITY; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; MALE; PARAMETRIC TEST; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SAMPLER; TEST RETEST RELIABILITY; TISSUE PERFUSION; TUMOR VOLUME;

AGED; ANGIOGRAPHY; ARTERIES; BLOOD VOLUME; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; OXYGEN RADIOISOTOPES; PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; WATER;

EID: 79851474264     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.079137     Document Type: Article

References (32)

1. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-410. (Pubitemid 37328844)
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
3. Demetri GD, Van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329-1338. (Pubitemid 44528723)
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134. (Pubitemid 46089673)
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
7. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.
8. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
9. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550. (Pubitemid 44917502)
10. Horger M, Lauer UM, Schraml C, et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multi-kinase inhibitor sorafenib. BMC Cancer. 2009;9:208.
11. Van Cruijsen H, Van der Veldt A, Hoekman K. Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions. Front Biosci. 2009;14:2248-2268.
12. Van der Veldt AA, Meijerink MR, Van den Eertwegh AJ, et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res. 2008;14:2431-2436. (Pubitemid 351551077)
13. Van der Veldt AA, Meijerink MR, Van den Eertwegh AJ, Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer. 2010;102:803-809.
14. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol. 2003;21:2823-2830. (Pubitemid 46621829)
15. De Langen AJ, Van den Boogaart V, Marcus JT, Lubberink M. Use of H2(15)OPET and DCE-MRI to measure tumor blood flow. Oncologist. 2008;13:631-644.
16. Hendrikse NH, Luurtsema G, Van der Veldt AA, Lubberink M. Positron emission tomography for modeling pathophysiological processes in vivo. Curr Opin Drug Discov Devel. 2008;11:717-725.
17. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002;20:3804-3814.
18. Van der Veldt AA, Luurtsema G, Lubberink M, Lammertsma AA, Hendrikse NH. Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance. Curr Pharm Des. 2008;14:2914-2931.
19. Hoekstra CJ, Stroobants SG, Hoekstra OS, Smit EF, Vansteenkiste JF, Lammertsma AA. Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. Clin Cancer Res. 2002;8:2109-2115.
20. 15O-labeled water and PET. J Nucl Med. 2008;49:1763-1768.
21. Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-off-light imaging capabilities. J Nucl Med. 2007;48:471-480. (Pubitemid 47604933)
22. 15O]CO gas production, monitoring and quality control system. Appl Radiat Isot. 1993;44:631-634.
23. Boellaard R, Van Lingen A, Van Balen SC, Hoving BG, Lammertsma AA. Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med. 2001;28:81-89. (Pubitemid 32120810)
24. 15O]water. J Nucl Med. 2000;41:1784-1792.
25. 15O-water and PET using the basis function method. J Nucl Med. 2005;46:1219-1224.
26. 15O-water and positron emission tomography. Mol Imaging Biol. 2005;7:273-285.
27. Hermansen F, Rosen SD, Fath-Ordoubadi F, et al. Measurement of myocardial blood flow with oxygen-15 labelled water: comparison of different administration protocols. Eur J Nucl Med. 1998;25:751-759. (Pubitemid 28377039)
28. Boellaard R, Hoekstra O, Lammertsma A. Software tools for standardized analysis of FDG whole body studies in multi-center trials [abstract]. J Nucl Med. 2008;49(suppl 1):159P.
29. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716-723.
30. Schwarz G. Estimating the dimension of a model. Ann Statist. 1978;6:461-464.
31. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310. (Pubitemid 16134762)
32. 15O and a clinical PETCT scanner [abstract]. J Nucl Med. 2010;51(suppl 2):47.